[2]thienylmethyl-carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: [2]thienylmethyl-carbamic acid
• 英文别名: [2]Thienylmethyl-carbamidsaeure；Thiophen-2-ylmethylcarbamic acid
• 化学式: C₆H₇NO₂S
• 分子量: 157.193
• InChiKey: KEJSIEWJWLSTAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  77.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [2]thienylmethyl-carbamic acid 、 (RS)-3-acetyl-4-chloro-2,2,5,5-tetramethyl-3-thiazolidine 反应 4.0h， 生成 (RS)-3-acetyl-4-(thiophen-2-ylmethyl)carbamoyloxy-2,2,5,5-tetramethyl-1,3-thiazolidine
  参考文献：
  名称：

  在环境条件下首次无催化剂捕获N-酰基亚胺离子的CO 2：硫代和恶唑烷二基氨基甲酸酯的可持续多组分合成

  摘要：

  报道了通过原位生成的氨基甲酸（二氧化碳（CO 2）和胺的产物）首次捕获N-酰亚胺离子。这种无催化剂的反应提供了一种方便，可行的方法，可以在绿色条件下以良好的官能团相容性和高效率来制备N-酰基硫代噻唑烷基和恶唑烷基氨基甲酸酯。此外，多组分方法具有广泛的底物范围，简便的产品多样化，平滑的放大规模以及在聚合物领域的显着潜力。

  DOI：

  10.1039/c8ob01865k
• 作为产物：
  描述：

  2-噻吩甲胺 生成 [2]thienylmethyl-carbamic acid
  参考文献：
  名称：

  噻吩的氨甲基化；改进了2-噻吩胺的合成。

  摘要：

  DOI：

  10.1021/ja01192a014

文献信息

• [EN] NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 2-PIPERIDIN-1-YL-ACETAMIDE UTILISABLES EN TANT QU'INHIBITEURS DE TANKYRASE
  申请人：NOVARTIS AG

  公开号：WO2013012723A1

  公开（公告）日：2013-01-24

  The present invention provides for compounds of formula (I), wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

  本发明提供了式(I)的化合物，其中R1-R5和L在此处定义。本发明还提供了包含式(I)化合物的药物组合物和组合物，以及将这些化合物用作坦基酶抑制剂以及用于治疗Wnt信号和坦基酶1和2信号相关疾病的用途，包括但不限于癌症。
• [EN] 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS<br/>[FR] DÉRIVÉS DE 4,5-DIHYDROISOXAZOLE UTILISÉS COMME INHIBITEURS DE NAMPT
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014111871A1

  公开（公告）日：2014-07-24

  The present invention provides substituted 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly NAMPT inhibitors and in which R1 R2, Y, X, "Het" and "p" have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salts or stereoisomers or N-oxide thereof.

  本发明提供了式(I)的取代4,5-二氢异噁唑衍生物，可能在治疗上有用，更具体地是NAMPT抑制剂，其中R1、R2、Y、X、“Het”和“p”的含义如规范中所述，并且它们的药学上可接受的盐，在哺乳动物中治疗和预防由尼古酰胺磷酸核糖转移酶(NAMPT)水平升高引起的疾病或紊乱。本发明还提供了化合物的制备以及包含式(I)的取代4,5-二氢异噁唑衍生物中至少一个或其药学上可接受的盐或立体异构体或N-氧化物的制药配方。
• Aminopyrazole Derivatives as Gsk-3 Inhibitors
  申请人：Benbow W. John

  公开号：US20070276010A1

  公开（公告）日：2007-11-29

  The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R 1 , R 2 , and R 3 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof in the treatment of, inter alia, conditions, diseases, and symptoms including, inter alia, Alzheimer's Disease, cancer, dementia, depression, diabetes, hair loss, schizophrenia, and stroke.

  本发明提供了式(I)的化合物及其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐，其中R1、R2和R3如本文所定义；其制备的药物组合物；以及其在治疗阿尔茨海默病、癌症、痴呆、抑郁症、糖尿病、脱发、精神分裂症和中风等病症和症状中的使用。
• NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS
  申请人：Cheung Atwood Kim

  公开号：US20150025070A1

  公开（公告）日：2015-01-22

  The present invention provides for compounds of formula (I): wherein R 1 -R 5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

  本发明提供了公式（I）的化合物：其中R1-R5和L在此定义。本发明还提供了含有公式（I）化合物的药物组合物和组合物，以及将这些化合物用作坦克酶抑制剂和治疗与Wnt信号和坦克酶1和2信号相关的疾病的用途，包括但不限于癌症。
• Agonists that enhance binding of integrin-expressing cells to integrin receptors
  申请人：Texas Heart Institute

  公开号：EP2881392A1

  公开（公告）日：2015-06-10

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法，包括在体外用整合素的激动剂处理表达整合素的细胞，其中整合素选自由α4β1、α5β1、α4β7、αvβ3和αLβ2组成的组，并使处理过的细胞与整合素结合配体接触；具有通式Ⅰ的整合素激动剂化合物；用这种激动剂处理整合素表达细胞以增强结合的方法；以及治疗方法，包括给哺乳动物施用激动剂处理过的细胞或激动剂化合物。